TickerFacts.

Inmune Bio, Inc. (INMB): Revenue

Annual figures by period end, from SEC filings.

$50.0K
Year ended 2025-12-31
-48.9%
3-year compound annual growth
+35.4%
5-year compound annual growth
$374.0K2017-12-31: $02018-12-31: $02020-12-31: $11.0K2021-12-31: $181.0K2022-12-31: $374.0K2023-12-31: $155.0K2024-12-31: $14.0K2025-12-31: $50.0K$50.0K
2017-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$50.0K+257.1%2026-03-30, From 2025-01-01
2024-12-31$14.0K-91.0%2026-03-30, From 2024-01-01
2023-12-31$155.0K-58.6%2025-03-27, From 2023-01-01
2022-12-31$374.0K+106.6%2024-03-28, From 2022-01-01
2021-12-31$181.0Kn/m2023-03-02, From 2021-01-01
2020-12-31$11.0Kn/a2022-03-03, From 2020-01-01
No annual figure between 2018-12-31 and 2020-12-31.
2018-12-31$0n/a2019-03-29, From 2018-01-01
2017-12-31$0n/a2019-03-29, From 2017-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Inmune Bio, Inc. (INMB)2025-12-31$50.0K+257.1%
Entera Bio Ltd. (ENTX)2025-12-31$42.0K-76.8%
AIM ImmunoTech Inc. (AIM)2025-12-31$88.0K-48.2%
Senti Biosciences Holdings, Inc. (SNTI)2025-12-31$22.0Kn/a
VivoSim Labs, Inc. (VIVS)2026-03-31$131.0K-9.0%
Zivo Bioscience, Inc. (ZIVO)2024-12-31$157.2K+468.6%
aTYR PHARMA INC (ATYR)2025-12-31$190.0K-19.1%
Creative Medical Technology Holdings, Inc. (CELZ)2025-12-31$6.0K-45.5%
Cardiff Oncology, Inc. (CRDF)2025-12-31$593.0K-13.2%

Compare INMB, ENTX, AIM, SNTI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗